Thrombotic Risk Minimization for Diane-35 and Generics
September 2017
in “
Pharmacoepidemiology and Drug Safety
”
TLDR The use of Diane-35 and its generics significantly decreased in the Netherlands.
The document presented a descriptive analysis that demonstrated similar proportions of cyproterone acetate/ethinylestradiol (CPA/EE) users with acne or other hyperandrogenic conditions, recent acne treatment, or concurrent use of other hormonal contraceptives in the Netherlands, both before and after a referral procedure. The primary finding was a significant overall decrease in the use of CPA/EE in the Netherlands.
